Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
By Reisa A. Sperling, P. Aisen, L. Beckett, David A. Bennett, S. Craft, Anne M. Fagan, T. Iwatsubo, Clifford R. Jack Jr., J. Kaye, Thomas J. Montine and 11 more. Alzheimer's & Dementia, 2011
6,812 citations recorded by the source corpus.
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Subfields: Pharmacology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/4718e61de2c928d77780b2a72fac704f18d8297b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
- Kaj Blennow
- Harald Hampel
- Marie Odile Habert
- Habib Benali
- Dennis W. Dickson
- Jeffrey L. Cummings
- Suzanne L. Baker
- William J. Jagust
In Physiology
- Clifford R. Jack Jr.
- Kaj Blennow
- Reisa A. Sperling
- John C. Morris
- Ronald C. Petersen
- Dennis W. Dickson
- J. Burns
- William J. Jagust
In Psychiatry and Mental health
- Clifford R. Jack Jr.
- Kaj Blennow
- Ronald C. Petersen
- Reisa A. Sperling
- John C. Morris
- Dennis W. Dickson
- William J. Jagust
- David S. Knopman
Citations in the corpus
- The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception (2011, neutral): “It is now generally accepted that the initial AD pathology develops in situ while the patient is cognitively normal, sometimes termed the “preclinical stage” [18,19].”
- The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy (2016, background): “The National Institute on Aging and the Alzheimer's Association has revised the criteria and guidelines whichwill better identify the disease progression from its preclinical stage to the clinical stage (Sperling et al., 2011).”
- NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, positive): “In the case of preclinical AD, biomarkers were used to define the construct [4].”
- Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease (2016, neutral): “Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
- Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease (2017, background): “plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”